Avineuro Pharmaceuticals, Inc.
A Global Neuroscience Research And Development Company Developing novel small molecules to treat unmet medical needs in the neurological and psychiatric fields.

San Diego, CA – June 22nd, 2009 – Avineuro Pharmaceuticals, Inc. announced today an initiation of a two-armed, double-blinded, placebo- and a reference drug- controlled Phase II clinical studies of AVN-397, a potent small molecule for treatment of anxiety and Alzheimer’s disease. Avineuro Pharmaceuticals, Inc. will present at ICAD 2009 in Vienna, Austria in July.

Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com